2
Clinical Trials associated with Alpha fetoprotein plasmid DNA vaccine(Jonsson Comprehensive Cancer Center)A Phase I/II Trial Testing Immunization With AFP + GM-CSF Plasmid Prime And AFP Adenoviral Vector Boost In Patients With Hepatocellular Carcinoma (AFP Prime-Boost Protocol)
RATIONALE: Vaccines made from DNA and a gene-modified virus may make the body build an immune response to kill tumor cells. Giving booster vaccinations may make a stronger immune response and prevent or delay the recurrence of liver cancer.
PURPOSE: This phase I/II trial is studying the side effects and best dose of vaccine therapy and to see how well it works in treating patients with stage II, stage IIIA, stage IIIB, or stage IVA liver cancer.
Phase I/II Trial Testing Alpha Fetoprotein (AFP) Peptide Immunization in Hepatocellular Carcinoma
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.
PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients who have liver cancer.
100 Clinical Results associated with Alpha fetoprotein plasmid DNA vaccine(Jonsson Comprehensive Cancer Center)
100 Translational Medicine associated with Alpha fetoprotein plasmid DNA vaccine(Jonsson Comprehensive Cancer Center)
100 Patents (Medical) associated with Alpha fetoprotein plasmid DNA vaccine(Jonsson Comprehensive Cancer Center)
100 Deals associated with Alpha fetoprotein plasmid DNA vaccine(Jonsson Comprehensive Cancer Center)